Revolutionizing Gene Therapy Manufacturing: The Pro10™ Cell Line Overcomes Challenges with Recombinant Adenovirus Production.

A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

In recent years, gene therapy manufacturing has faced numerous challenges, including inefficiencies and scalability issues associated with recombinant adeno-associated virus (rAAV) production. To address these challenges, a new technology has been developed: the Pro10™ cell line. This proprietary mammalian suspension technology is designed to enhance the efficiency and scalability of rAAV production for gene therapy manufacturing.

The Pro10™ cell line has been fully characterized and licensed for gene therapy development by various biopharmaceutical companies. It is a reliable and scalable rAAV vector manufacturing process that utilizes these cells as its core. The Pro10™ cells have been optimized specifically for rAAV production and have successfully scaled up to 2000L, achieving consistent and reproducible cell growth rates. They are capable of producing various AAV serotypes in both small and large-scale bioreactors.

One company that has adopted this technology is Viralgen, which uses the Pro10™ cells as the backbone of its platform process for manufacturing AAV vectors. The company’s use of this technology has significantly contributed to the production of innovative gene therapies, reducing process development time and costs in the process. For more information about the HEK293 derived animal component-free suspension Pro10™ cell line, access the full PDF detailing its capabilities and benefits for gene therapy manufacturing.

Leave a Reply